Compare ATMU & IRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATMU | IRTC |
|---|---|---|
| Founded | 1958 | 2006 |
| Country | United States | United States |
| Employees | N/A | 2400 |
| Industry | Auto Parts:O.E.M. | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.4B | 3.7B |
| IPO Year | 2023 | 2016 |
| Metric | ATMU | IRTC |
|---|---|---|
| Price | $44.17 | $109.28 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 13 |
| Target Price | $58.25 | ★ $197.92 |
| AVG Volume (30 Days) | ★ 495.2K | 464.4K |
| Earning Date | 05-01-2026 | 04-30-2026 |
| Dividend Yield | ★ 0.36% | N/A |
| EPS Growth | 12.61 | ★ 61.71 |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $1,764,300,000.00 | $747,138,000.00 |
| Revenue This Year | $15.00 | $19.60 |
| Revenue Next Year | $5.13 | $15.94 |
| P/E Ratio | $32.27 | ★ N/A |
| Revenue Growth | 5.67 | ★ 26.24 |
| 52 Week Low | $42.60 | $100.85 |
| 52 Week High | $66.50 | $210.01 |
| Indicator | ATMU | IRTC |
|---|---|---|
| Relative Strength Index (RSI) | 30.11 | 37.78 |
| Support Level | N/A | $102.62 |
| Resistance Level | $54.95 | $127.33 |
| Average True Range (ATR) | 1.37 | 4.62 |
| MACD | -0.24 | -1.21 |
| Stochastic Oscillator | 7.48 | 10.36 |
Atmus Filtration Technologies Inc manufactures filtration products for on-highway commercial vehicles and off-highway agriculture, construction, mining, and power generation vehicles and equipment. The company designs and manufactures Developed filtration products, principally under the Fleetguard brand, that enable lower emissions and provide asset protection. It designs, manufactures, and sells filters, coolants, and chemical products. The company offers products including air filtration, coolants and chemicals, crankcase ventilation, fuel filtration, fuel cells, lube filtration, and others.
iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.